SIBN vs UFPT
SIBN: SI-BONE is a medical device company providing minimally invasive surgical solutions to treat conditions of the sacroiliac joint and spinopelvic anatomy. UFPT: A specialized contract manufacturer producing custom single-use and single-patient medical devices for major OEMs across minimally invasive surgery, wound care, orthopedics, and biopharma applications.
Side-by-side fundamentals
| Metric | SIBN | UFPT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.71 | $237.96 | |
| Market cap as of 2026-07-23 | $744M | $1.9B | |
| P/E as of 2026-07-23 | n/a | 27.03 | |
| PEG as of 2026-07-23 | n/a | 3.50 | |
| Net margin as of 2026-07-23 | -8.1% | +11.3% | UFPT higher |
| Gross margin as of 2026-07-23 | +79.6% | +28.4% | SIBN higher |
| Operating margin as of 2026-07-23 | -9.7% | +15.2% | UFPT higher |
| ROE as of 2026-07-23 | -9.6% | +16.6% | UFPT higher |
| ROA as of 2026-07-23 | -7.1% | +10.5% | UFPT higher |
| Debt / equity as of 2026-07-23 | 0.20 | 0.31 | SIBN lower |
| Revenue growth (YoY) as of 2026-07-23 | +16.8% | +11.2% | SIBN higher |
| Revenue CAGR (3y) SEC XBRL | +23.6% | +22.7% | SIBN higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 0.71 | 1.07 | |
| 1-year return as of 2026-07-22 close | -2.6% | +3.0% | UFPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.